Medicare Compliance: Mandatory MFN Model for Part B Reimbursement
Model Participants, Subject Drugs, Payment Methodology and Add-on Payments, Price Reporting
A live 90-minute CLE video webinar with interactive Q&A
This CLE webinar will analyze key issues arising out of the Most Favored Nation (MFN) Interim Final Rule for Medicare Part B reimbursement for drugs and biologics. The panel will discuss the implications for Medicare reimbursement and the impact on drug manufacturers, healthcare providers. and patients. The panel will also summarize the status of litigation challenging the Interim Final Rule.
- MFN Interim Final Rule
- Model participants
- Drugs and biologics subject to model
- Payment methodology
- Add-on payments
- Manufacturer price reporting
- Provider hardship exemption
- Beneficiary protections
- Implications for healthcare provider reimbursement
- Implications for manufacturers
- Status of litigation challenging the Interim Final Rule
The panel will review these and other key issues:
- What is the nature and scope of the MFN Model?
- How will the MFN Model affect Medicare Part B reimbursement for drugs and biologics?
- How will be MFN Model impact drug manufacturers? Hospitals? Physicians? Other providers?
- What is the status of litigation challenging the MFN Model?
David J. Farber
King & Spalding
Mr. Farber specializes in litigation, regulatory matters, and public policy, with a focus on healthcare, Medicare and... | Read More
Mr. Farber specializes in litigation, regulatory matters, and public policy, with a focus on healthcare, Medicare and Medicaid issues for pharmaceutical and medical device companies, hospitals and pharmacies. A member of the firm’s FDA, Life Sciences, and Healthcare, and Government Advocacy practices, he represents clients in healthcare litigation, False Claims Act cases and other commercial disputes, as well as in advocacy before Congress and federal agencies on coverage, coding, reimbursement and other issues. Mr. Farber is a recognized national expert on Medicare Secondary Payer issues.Close
Preeya Noronha Pinto
King & Spalding
Ms. Pinto assists life science manufacturers with strategic reimbursement planning during all stages of the product... | Read More
Ms. Pinto assists life science manufacturers with strategic reimbursement planning during all stages of the product life cycle. She also engages in healthcare regulatory and policy advocacy before government agencies and the U.S. Congress. A former HHS Acting General Counsel and DOJ litigator, Ms. Pinto helps healthcare clients seek regulatory and policy change and combat adverse government action arising from the Medicare and Medicaid programs, FDA regulation, fraud and abuse matters, and ongoing healthcare reform. She represents pharmaceutical and medical device manufacturers, clinical laboratories, and other healthcare suppliers and providers in a wide range of healthcare policy and regulatory matters. Ms. Pinto helps clients design and execute reimbursement strategies for drugs and medical devices, including navigating and anticipating the complex and changing world of coverage, coding and payment, particularly with regard to emerging technologies.Close
Buy Live Webinar
Buy Live Webinar & Recording
A savings of $200
Live Webinar & Download
Live Webinar & DVD
$394 + $24.45 S&H